<DOC>
	<DOCNO>NCT02881073</DOCNO>
	<brief_summary>The primary aim establish effectiveness plasma PlGF measurement reduce maternal morbidity ( assessment perinatal safety parallel ) woman present suspected pre-eclampsia prior 37 week ' gestation . The long term aim demonstrate knowledge PlGF measurement enables appropriate stratification antenatal management woman present suspected pre-eclampsia , high risk receive great surveillance decrease maternal adverse outcome , low risk manage without unnecessary admission intervention , result would influence international clinical practice antenatal patient healthcare</brief_summary>
	<brief_title>Placental Growth Factor Assessment Women With Suspected Pre-eclampsia</brief_title>
	<detailed_description>Pre-eclampsia ( PET ) , disease late pregnancy characterise hypertension proteinuria , complicate 2-8 % pregnancy associate significant maternal neonatal morbidity mortality . Many report highlight frequent substandard care , often attribute clinician identify seriousness clinical sign suggestive disease . Consequently , improvement prediction development PET potential vastly improve clinical outcome reduce cost . Placental Growth Factor ( PlGF ) belong vascular endothelial growth factor ( VEGF ) family represent key regulator angiogenic event pathological condition . PlGF exert biological function bind activation receptor Flt-1 . In PET , think endothelial dysfunction lead increase level circulate decoy receptor , know soluble Flt-1 , ( sFlt-1 ) , soluble receptor VEGF-A PlGF . In 2013 , INFANT team part international group publish first multicentre prospective study ( PELICAN ) evaluate use PlGF woman present suspected PET , report high sensitivity ( 95-96 % ) negative predictive value ( 95-98 % ) low PlGF determine need delivery confirm PET within 14 day . This study suggest PlGF test present realistic innovative adjunct management woman suspect PET , especially present preterm .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Eclampsia</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Pregnant woman 20+0 36+6 week gestation ( inclusive ) Singleton pregnancy Aged 18 year Able give inform consent , present symptom suspect preeclampsia Headache visual disturbance epigastric right upper quadrant pain increase oedema hypertension dipstick proteinuria suspect fetal growth restriction healthcare provider deem woman require evaluation possible preeclampsia Confirmed preeclampsia point enrolment ( sustain hypertension systolic BP ≥ 140 diastolic BP ≥ 90 least two occasion least 4hrs apart ) significant quantify proteinuria ( &gt; 300mg protein 24hr collection urine protein creatinine ratio &gt; 30mg/mmol ) &gt; 37 week gestation Abnormal PET blood Multiple pregnancy time point Decision regard delivery already make Lethal fetal abnormality Previous participation PELICAN trial prior pregnancy Plan use protocol PIGF test Unable/unwilling give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Placental Growth Factor</keyword>
	<keyword>Maternal Morbidity</keyword>
	<keyword>Neonatal Morbidity</keyword>
	<keyword>Pre-eclampsia</keyword>
	<keyword>Heath Economics</keyword>
</DOC>